← back to picks

Reporting EUR Credit synthetic A1/A+ Valuation date 2026-05-25 Damodaran FCFF · 1000-iter MC Industry Chemical (Specialty) Scenario STANDALONE (deal-break) FCFF · Dark v3

Standalone fair value above market · +18.3% MoS

BUY thesis even without the Axalta merger closing

AkzoNobel STANDALONE (no merger synergies, no special dividend, no re-rating): intrinsic per-share €60.00 vs market €49.04, +18.3% MoS post 5% governance haircut. Council-revised to 11% year-10 op margin (top of 10y band, not above it) and sales-to-capital 1.2 (9% premium to Chemical-Specialty median, not 36%). P(undervalued in standalone) = 88.1% across 1,000 MC iterations. The Axalta merger (Goldman SoTP €95/sh on close) is upside on top — see MergeCo sibling.

Chemical (Specialty)EMEA ~48% · APAC ~25% · Americas ~25%#3 global paints+coatings (~7% share)Activist Cevian 10% (supportive)MC σ €8.11/shGov haircut 5%STANDALONE only — Axalta = call option

Intrinsic / share

€60.00

post 5% gov (€63.16 → €60.00) · STANDALONE

Market / share

€49.04

Euronext Amsterdam · AKZA

Margin of safety

+18.3%

vs intrinsic

Enterprise value

€13.91B

65.7% terminal

Cost of equity / debt

8.84% / 2.30%

β 1.18 · CRP 1.24%

Terminal ROIC / g

8.90% / 2.40%

terminal ROC 8.9% vs WACC 6.44%

What it sells, where it sells

Operating segments — FY2025 revenue €10.16B

Decorative PaintsDulux, Sikkens, Flexa — brand pricing power~46%

Industrial & PowderInterpon — cyclical~30%

Marine, Protective, Aerospacespecialty mix~14%

Automotive & Specialtyrefinish/OEM~10%

FY2025 continuing-ops mix post-India deconsolidation. Decorative is the brand-pricing-power anchor (Dulux UK, Sikkens DE/FR/BeNe) — also bears the steepest margin compression in the current cycle. Performance Coatings industrial sub-segments drove the four-consecutive-quarter margin expansion through Q1 2026.

Country mix (revenue-weighted CRP input)

🇨🇳China15.0%

🇧🇷Brazil12.0%

🇬🇧United Kingdom12.0%

🇳🇱Netherlands10.0%

🇺🇸United States10.0%

🇩🇪Germany8.0%

🇫🇷France6.0%

🇹🇷Turkey4.0%

🇲🇽Mexico4.0%

🇮🇩Indonesia4.0%

🇮🇹Italy3.0%

🇪🇸Spain3.0%

🇯🇵Japan3.0%

🇸🇪Sweden2.0%

🇧🇪Belgium2.0%

🇦🇺Australia2.0%

Region-disclosure decomposed to 16-country revenue mix. EMEA (~48%) split across UK/NL/DE/FR/IT/ES/SE/TR/BE; Asia Pacific (~25%) dominated by China; Americas (~25%) split Brazil/Mexico/US. India excluded (divested Dec-2025). Weighted CRP lands at 1.24% — EM exposure (China/Brazil/Turkey/Indonesia/Mexico) lifts the blend modestly above the pure-DM benchmark.

Background — five things to know before the case

Context the share price doesn't carry on its face. Skim this once and the bull / bear bullets below stop reading as inside baseball.

#3 global paints + coatings player, ~€10.2B FY2025 continuing-ops revenue. ~7% global share, ~16% European share. Headquartered Amsterdam, listed Euronext (AKZA.AS). Two halves: Decorative Paints ~46% (Dulux, Sikkens, Flexa — brand-heavy pricing power) and Performance Coatings ~54% (industrial, powder, marine, protective, aerospace, automotive, refinish).
2018 Specialty Chemicals divestment reset the scope. Sold to Carlyle for €10.1B; €6.5B returned to shareholders 2018-2019. The current company is the pure-play paints+coatings remainder of that split — a different beast from the pre-2018 chemicals conglomerate.
India closed Dec-2025 (~€500-700M annualized revenue out). FY2026 numbers carry an India step-down drag in Y1; from FY2027 the comp base is clean. This is why Y1-5 revenue growth at 2.6% looks below the demonstrated 2018-2024 ~2.4% CAGR baseline.
Cevian holds ~10% activist stake, supportive of strategy continuity. Built Aug-Dec 2025. Combined with Dodge & Cox ~10% = ~20% in two institutional hands. Not adversarial — Cevian wants Poux-Guillaume's industrial-transformation programme to keep running.
Axalta merger signed 18-Nov-2025 — call option, NOT in this number. Goldman M&A SoTP €95/sh on close vs €60 standalone. Antitrust review ongoing; €2.5B pre-close special dividend (~€14.6/sh) is conditional on closing. Standalone DCF here is the deal-break floor — see akza-mergeco.yaml sibling for the close scenario.

Continuing-ops revenue path 2018→2025: €9.3B → €10.7B → €10.16B (~2.4% CAGR, with the FY2025 step-down reflecting partial-year India deconsolidation). Adjusted EBIT margin compressed from a 2018 ~11% peak to a 2022 ~7.3% trough during the raw-material spike, then recovered to FY2025 ~14.2% (true reported including +€83M positive identified items: India divestment gain, Australian litigation, restructuring). Four consecutive quarters of margin expansion through Q1-2026 (14.5% adj EBITDA, +80bps YoY) under CEO Greg Poux-Guillaume's €250M industrial-transformation programme. Activist Cevian Capital built a >10% stake Aug-Dec 2025, explicitly endorsing existing strategy. Pending Axalta merger of equals signed 18-Nov-2025, expected close late-2026/early-2027 — this report values the STANDALONE deal-break scenario.

Where we diverge from the sector

Each row asks: if we'd used the sector median for this one assumption instead of our override, how much would the share price change? Negative = our override is more conservative (worth less); positive = more aggressive (worth more). Skim down the rightmost column to see which bets are doing the work.

Assumption

Our input

Sector median

Value impact

01Revenue growth10-year CAGR

~2.5% CAGR€10.16B → ~€13.0B by Y10

~3.0%Chemical-Specialty median, 10-yr

−€1.50

02Operating marginYear-10 steady state

11.0%Council-revised from 13% — top of 10y adj-EBIT band

12.2%Chemical-Specialty median

−€5.00

03Sales-to-capitalReinvestment efficiency

1.20Brand-heavy decorative premium (Dulux, Sikkens)

1.10Chemical-Specialty median

+€1.20

04Terminal growthYear 10+ steady state

2.4%EUR risk-free ceiling

2.4%at the ceiling — no override

€0.00

05Cost of capitalWACC, 10-year average

6.44%β 1.18 · CRP 1.24% (EM blend) · EUR rf 2.4%

~6.6%pure-chemical WACC, no EM CRP add-on

−€0.30

Net effect of overrides

Overrides net −€5.60/share vs all-defaults · the council-revised margin haircut (11% vs sector 12.2%) is the largest single drag, partly offset by a brand-defensible sales-to-capital premium. Even with these conservative overrides the model lands at €60.00 vs €49.04 market — the +18% margin of safety doesn't come from cherry-picked assumptions, it comes from operations the market is mispricing.

−€5.60

Our override Sector median Override adds value Override subtracts value

The story & the five claims

The 10-year story this DCF is built on, plus the five anchor claims that translate the story into engine inputs.

The 10-year story

AkzoNobel standalone is a mature European specialty-chemicals consolidator emerging from two scope-resetting cliffs (2018 Specialty divestment, 2025 India sale) and the 2021-22 raw-material margin trough. The pure paints+coatings business compounded ~2.4% through cycle; the central read is GDP-plus 2.6% Y1-5 ramping to EUR risk-free 2.4% terminal, with adjusted operating margin compounding from FY2025's 14.2% high (with positive identified items) toward council-revised steady-state 11% — top of the historical 10y adj-EBIT band, modest premium to Damodaran Chemical-Specialty median 12.2%, consistent with brand-heavy Dulux/Sikkens pricing power and the demonstrated four-consecutive-quarter expansion under Poux-Guillaume's industrial transformation. Cevian's supportive activist stake backs strategy continuity. Iran raw-mat shock and 6-month pricing-lag are sized in the Monte Carlo, not in the base. The Axalta merger upside — Goldman's M&A SoTP €95/sh on close — is treated as a separate call option valued in the MergeCo sibling YAML; this standalone DCF is the deal-break floor.

Two debates worth pressure-testing

Q. Does the Axalta merger close (late-2026/early-2027)?

Signed 18-Nov-2025, antitrust review ongoing. Goldman's M&A SoTP = €95/sh on close vs €47 standalone — a binary catalyst not in this base case. See akza-mergeco.yaml sibling for the deal-close fan.

Q. Iran/Strait of Hormuz raw-mat shock — transient or sustained?

March 2026 +19% MoM basket; ~50% cost base oil-linked. Mgmt says "already announced price increases fully compensate"; Goldman cuts FY26 EBITDA -8.4% on 6-month pricing lag. Sized in MC (margin axis pulled down 200bps at p5).

Q. Why did Goldman cut Buy→Neutral (Apr 2026) while Berenberg stays Buy?

GS prices the wrapper (pricing lag + sustained volume weakness since 2018); Berenberg prices the option (war de-escalation + Axalta upside). Both are right about different time horizons — Q1 +80bps margin print suggests near-term execution is intact.

Q. Is the council-revised 11% year-10 op margin too conservative?

Council Contrarian: prior 13% was ABOVE the 10y adj EBIT band top — heroic disguised as base. 11% sits AT the top of the band (6-11% range) and credits Q1's 4-cons-qtr expansion + €250M transformation programme without assuming regime change.

Q. Sales-to-capital 1.2 vs Damodaran median 1.10 — fair premium?

9% premium for brand-heavy Dulux/Sikkens decorative mix is defensible. Council cut from 1.5 (a 36% premium) on a business whose ROIC compressed 15%→8% — "two miracles, not one."

CLAIM 01 Revenue compounds €10.16B → ~€13.0B by 2035. 2.6% Y1-5 → 2.4% Y10 (terminal = EUR risk-free) GDP-plus 3% organic less FY2026 India step-down drag; sits inside demonstrated 2018-2024 ~2.4% continuing-ops CAGR.

CLAIM 02 Year-10 op margin 11% — top of historical band. 11.0% (council-revised from 13%, FY25 base 14.2%) Credits the four-consecutive-quarter margin expansion (Q2-25 → Q1-26) and the €250M transformation programme without assuming regime change.

CLAIM 03 Sales-to-capital 1.2 — 9% premium to sector median. 1.20 vs Damodaran Chemical-Specialty 1.10 Brand-heavy Dulux/Sikkens decorative mix justifies modest premium. Council cut from 1.5 (a 36% premium on a business whose ROIC compressed 15%→8%).

CLAIM 04 Margin converges by Y5; growth by Y10. Y5 = 2030, mature consolidator path ~3 years past the 2027 transformation milestone — absorbs Iran shock and pricing-lag drag. Growth lands at EUR risk-free 2.4% per Damodaran ceiling.

CLAIM 05 Governance haircut 5% — standard public-company. 5% (range 0-10%, Damodaran default) No controlling shareholder; Cevian 10% supportive; CEO bought €1.5M shares Feb-2025 at €60.27. Residual reserved for Kepler's "follow-through" concern.

Where we diverge from sell-side

Why the market is at €49.04 and the standalone DCF is at €60.00: The market is pricing the wrapper (Iran/Hormuz raw-mat shock, 6-month pricing lag, sustained Decorative volume weakness since 2018, Goldman cutting Buy→Neutral, Barclays cutting OW→EW). The DCF prices the operations as they actually traded over the last decade: a #3 global player with brand pricing power, four consecutive quarters of margin expansion, and a mature 2.4% CAGR with the option to compound at GDP-plus from a cleaner post-India base. The Axalta merger (Goldman M&A SoTP €95/sh on close, +$600M run-rate synergies) is an explicit call option on top — NOT in this €60.00 standalone number. Even the joint p5 standalone bear (worst-case raw-mat × margin × growth combo) lands €45.90 — only -6% vs market. The bet is that either (a) operations re-rate as Q1-Q2 2026 margin prints continue beating, or (b) Axalta closes and the SoTP catalyst flows through, or (c) both. The Q2-2026 release (mid-July) is the next data point.

Two-sided case — bear anchors

Bear case (STANDALONE, P5 ≈ €45.90)

Iran raw-mat shock sustains 12-18 months — pricing lag bites a full cycle, FY26-FY27 margin reverts to 10-11% before recovery (Goldman scenario: -8.4% FY26 EBITDA cut)
Decorative Paints volume weakness extends — sustained since 2018, construction end-markets still soft, ~46% revenue exposure
Axalta merger BLOCKS at antitrust (paints+coatings consolidation already ~50% top-3 — regulator may force divestitures or kill the deal)
€250M industrial-transformation programme misses 2027 milestone — Kepler's "history of not following through" concern materializes
China property/decorative deceleration accelerates — APAC ~25% of revenue, China ~15% as single largest country exposure

Risks to thesis (tail, not bear case)

BASE-CASEIran/Hormuz raw-mat shock persistence

March 2026 basket +19% MoM; ~50% cost base oil-linked; 6-month backward-looking pricing lag. Goldman models -8.4% FY26 EBITDA hit. Asymmetric MC margin axis.

BASE-CASEDecorative volume weakness

~46% revenue exposure; volumes "under pressure on a sustained basis since 2018" per Goldman. Construction end-markets still soft in EMEA. Pricing power exhausted in recent inflation cycle.

HIGHAxalta merger blocks at antitrust

Top-3 consolidation already ~50% global share. Regulator may force divestitures (synergies shrink) or kill the deal (call option expires worthless). Decision late-2026/early-2027.

HIGHChina APAC slowdown

China is single-largest country (~15% group revenue) across Decorative + Powder + Marine. Property-led decorative deceleration is a structural drag, not cyclical.

MEDIUMExecution risk on €250M transformation programme

Kepler: AkzoNobel has "history of not following through with plans." Q1 4-cons-qtr expansion suggests current mgmt is delivering; 2027 milestone is the test.

MEDIUMCevian exit (10% block overhang)

Activist Cevian built stake Aug-Dec 2025; track record 3-5y horizons. Eventual exit creates block-trade pressure. Combined with Dodge & Cox 10% = 20% in two institutional hands.

EXECUTIONEUR / FX translation

Reports in EUR; ~25% Asia + ~25% Americas revenue. EUR strength compresses reported growth — already a partial headwind FY2025.

EXECUTIONSpecial dividend timing

Pre-Axalta-close €2.5B special dividend (~€14.6/sh) is conditional on deal closing. Standalone valuation does NOT include this — it sits with the MergeCo scenario.

10-year forecast

Revenue €10.42B → €13.05B over 10y (~2.3% CAGR — pure paints+coatings trajectory post-India deconsolidation); op margin compounds from 12.1% to 11.00% by Y5 (council-revised down from 13% — top of historical 10y adj-EBIT band).

Monte Carlo distribution

P5 €45.90 sits ~-6% vs market €49.04 — even the joint 5th-percentile bear scenario (worst-case combo of revenue, margin, terminal growth, capital intensity) does not price below today's quote. P50 €58.70 is ~+20% above market; P(undervalued) = 88.1%. Note: this is the STANDALONE scenario — Axalta merger upside is a separate call option not modelled here.

1000 iterations randomising the central uncertainties (revenue growth, year-10 op margin, terminal growth, sales-to-capital, governance) with correlations from mc.yaml. P(intrinsic < market €49.04) = 11.9%.

Mean €58.96 ± €8.11/sh. P5 €45.90 · P25 €53.17 · P50 €58.70 · P75 €64.29 · P95 €73.20.

Sources & cross-references

Filings corpus digest: valuations/akza/filings/filings_corpus_digest.md — anchors for revenue-progression, margin-progression, roic-progression, guidance-consistency, cyclicality, competitive-positioning
Context check (sell-side + Q1 print): valuations/akza/context.md — 🟡 Mixed verdict (raw-mat shock vs four-cons-qtr margin expansion + Axalta merger + Cevian activism)
Council pressure-test (5 advisors): valuations/akza/council/ — drove revisions to year-10 op margin (13% → 11%) and sales-to-capital (1.5 → 1.2)
Country mix rationale (16-country revenue decomposition, EMEA/APAC/Americas split): valuations/akza/country_mix_rationale.md
Narrative + claim traces (5 claims, three-storyline verdicts): valuations/akza/narrative.md
Monte Carlo overlay: valuations/akza/mc.yaml (5 axes; revenue × margin × terminal × sales-to-capital × governance, with cross-correlations)
MergeCo sibling (Axalta close scenario): valuations/akza/akza-mergeco.yaml + output/2026-05-25-result-mergeco.json — the call-option-on-close fair value, NOT included in this standalone number
Engine result (full, STANDALONE): 2026-05-25-result-standalone.json
Damodaran data snapshot: ctryprem 2026-01-01 · industry_global 2026-01-01 · risk_free EUR 2024-09-01 (0.024)

⚠ terminal_growth (0.0240) >= risk_free_rate (0.0240); Damodaran's stable-growth ceiling is the risk-free rate

Cost of capital build

Risk-free rate	2.40%
Mature-market ERP	4.23%
Levered β	1.18
Weighted CRP	1.24%
Cost of equity	8.84%
Pre-tax cost of debt (synth A1/A+)	2.30%
D / V	~38%
WACC	6.44%

Full year-by-year DCF

Year	Revenue	Op mgn	EBIT	EBIT(1−t)	Reinvest	FCFF	PV
1	€10.42B	12.14%	€1.26B	€851M	€220M	€631M	€593M
2	€10.69B	11.85%	€1.27B	€853M	€226M	€627M	€554M
3	€10.97B	11.57%	€1.27B	€854M	€232M	€622M	€516M
4	€11.26B	11.28%	€1.27B	€855M	€238M	€617M	€481M
5	€11.55B	11.00%	€1.27B	€855M	€244M	€611M	€447M
6	€11.84B	11.00%	€1.30B	€895M	€246M	€648M	€445M
7	€12.14B	11.00%	€1.34B	€936M	€249M	€687M	€442M
8	€12.44B	11.00%	€1.37B	€978M	€251M	€727M	€438M
9	€12.75B	11.00%	€1.40B	€1.02B	€253M	€768M	€433M
10	€13.05B	11.00%	€1.44B	€1.07B	€255M	€811M	€427M

Methodology & flags

Damodaran FCFF DCF, 10y explicit + perpetuity. R&D capitalised (formulator R&D, €260M FY2025, 10y straight-line per Damodaran method). IFRS-16 leases already in book debt so lease-cap OFF to avoid double-count. Synthetic credit rating A1/A+. CRP from revenue-weighted 16-country mix × Damodaran 2026 CRPs. 5% governance discount applied post-DCF (standard public-company haircut — no controlling shareholder, activist Cevian supportive). Monte Carlo: 1000 iterations, 5 sampled axes with correlations. STANDALONE scenario — Axalta merger upside (≈$600M synergies, Goldman M&A SoTP €95/sh) is NOT in this base case; see akza-mergeco.yaml sibling for the deal-close fan. Engine v1.0.0 · result: 2026-05-25-result-standalone.json

R&D cap: ON · Lease cap: OFF · Failure: OFF · ESO: OFF
Governance haircut: 5% (€63.16 → €60.00)
Sensitivity tornado: not run (MC supersedes for this valuation)

FCFF DCF · dark theme v3. Generated 2026-05-25T17:00:34 from /Users/valentin/Documents/notes_jiliac_labs/Finance/Damodaran/valuations/akza/output/2026-05-25-result-standalone.json.